SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, Foxwoods Man, drkazmd65, maverick1856
Search This Board:
Last Post: 3/1/2015 10:48:41 PM - Followers: 162 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries 02/27/2015 03:22:00 PM
CVM News: FinancialBuzz.com Exclusive Interview With CEL-SCI CEO Geert Kersten From the Floor of the NYSE 02/23/2015 09:00:00 AM
CVM News: CEL-SCI To Participate in Ascendiant’s Quarterly Management Discussion Series Today, Friday February 20 at 11 Am Eastern Time 02/20/2015 08:00:00 AM
CVM News: CEL-SCI’s Phase III Head & Neck Cancer Trial Cleared to Begin Patient Enrollment in Malaysia, the 20th Country to Join the ... 02/19/2015 08:00:00 AM
CVM News: The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial 02/11/2015 08:00:00 AM
PostSubject
#6818  Sticky Note CEL-SCI (NYSE: CVM) is the most undervalued Phase maverick1856 02/27/15 01:26:17 PM
#6737  Sticky Note And then there were 20,.... drkazmd65 02/19/15 11:36:47 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6825   $CVM http://insidertrading.org/large-stock-buying.php?sort_by=acceptance_datetim JBD24 03/01/15 10:48:41 PM
#6824   Institutional Buying going on....first number after the name maverick1856 03/01/15 07:28:09 AM
#6823   No dilution or dump occurred. Just getting started JBD24 02/28/15 01:27:24 PM
#6822   ...and that would be a REALLY good thing Foxwoods Man 02/28/15 07:37:17 AM
#6821   A lawyer who is also married to a maverick1856 02/28/15 06:47:42 AM
#6820   Gert has done a great job in looking Turney 02/27/15 07:27:20 PM
#6819   http://finance.yahoo.com/news/cancer-drug-once-bought-7-020735961.html Sorry! ducruacuteo11 02/27/15 02:46:35 PM
#6818   CEL-SCI (NYSE: CVM) is the most undervalued Phase maverick1856 02/27/15 01:26:17 PM
#6817   http://www.stockta.com/cgi-bin/analysis.pl?symb=CVM&cobrand=&mode=stock Looki ducruacuteo11 02/27/15 11:40:45 AM
#6816   http://archive.constantcontact.com/fs141/1101855435216/archive/1120223807599.htm ducruacuteo11 02/27/15 11:36:28 AM
#6815   I would not street about any dilution...if there maverick1856 02/27/15 11:21:09 AM
#6814   They have enough cash to get them into maverick1856 02/27/15 11:17:23 AM
#6813   With our luck, somebody probably will unload a ducruacuteo11 02/27/15 11:11:09 AM
#6812   Absolutely but difficult to prove and who initiates/funds mikedel 02/27/15 10:42:40 AM
#6811   That would be considered insider trading.... maverick1856 02/27/15 09:53:29 AM
#6810   Possible reason for latest run. mikedel 02/27/15 08:49:14 AM
#6809   I think we test $1 tomorrow and possibly maverick1856 02/26/15 08:25:00 PM
#6808   I like your conviction! ducruacuteo11 02/26/15 03:00:32 PM
#6807   I wouldn't wait, you might not have another Turney 02/26/15 11:57:05 AM
#6806   I don't think we are in any real drkazmd65 02/26/15 10:49:43 AM
#6805   $10 - 100/share would be amazing...I would prefer maverick1856 02/25/15 04:37:12 PM
#6804   Geert said the CVM should be at about ducruacuteo11 02/25/15 03:35:57 PM
#6803   personally I would like to see arbitration/settlement of maverick1856 02/25/15 10:53:58 AM
#6802   Thanks, Maverick....late reply just returned home...if binding, let's sab63090 02/25/15 09:53:51 AM
#6801   Most of his 9m shares relates to the maverick1856 02/25/15 08:42:02 AM
#6800   see the below post maverick1856 02/25/15 08:34:29 AM
#6799   I agree but it is not volunteer work. Foxwoods Man 02/25/15 07:17:38 AM
#6798   Arbitration Scheduled for May 4th 2015. Binding or sab63090 02/25/15 06:54:46 AM
#6797   In Gert's interview @ the stock ex. He Turney 02/24/15 03:43:23 PM
#6796   Agreed FM,.... barring a very large, and very drkazmd65 02/24/15 12:08:09 PM
#6795   Phase III Trial sab63090 02/24/15 09:01:46 AM
#6794   Foxman I agree, the 880 number is hard maverick1856 02/24/15 08:26:34 AM
#6793   Nice synopsis and I agree with all except: Foxwoods Man 02/24/15 08:12:41 AM
#6792   I did too...I started building a position last maverick1856 02/24/15 08:07:17 AM
#6791   Nothing wrong with Geert pushing his company..(and his Foxwoods Man 02/24/15 08:02:23 AM
#6790   Thanks, Maverick....I went in recently (after money raise) sab63090 02/24/15 08:00:54 AM
#6789   Lol....I even provided the link, but missed that, thanks! sab63090 02/24/15 07:57:15 AM
#6788   I believe that these are the following issues maverick1856 02/24/15 07:52:41 AM
#6787   Assume yesterday's Sachs Cancer Bio NYC presentation @ sab63090 02/24/15 07:32:46 AM
#6786   2) CEL-SCI Corp. paid Streetwise Reports to conduct, Foxwoods Man 02/24/15 07:03:49 AM
#6785   CVM Cel-Sci mick 02/23/15 07:03:21 PM
#6784   GK: If head-and-neck cancer is all we ever maverick1856 02/23/15 04:43:44 PM
#6783   New Report.....link sab63090 02/23/15 03:47:11 PM
#6782   At least you have a choice. I ducruacuteo11 02/23/15 03:17:43 PM
#6781   Tonight's Presentation.....anyone invited? sab63090 02/23/15 02:30:22 PM
#6780   I would agree with that assessment...with an arbitration/settlement maverick1856 02/23/15 02:14:41 PM
#6779   The sooner the better. I am still ducruacuteo11 02/23/15 02:10:24 PM
#6778   you might want to adjust your timetable from maverick1856 02/23/15 01:33:55 PM
#6777   New CRO invested $10 Mil....I agree with the sab63090 02/23/15 01:30:32 PM
#6776   I finally had some free time today to ducruacuteo11 02/23/15 01:25:05 PM
PostSubject